Skip to content

A Comparison Between Titanium Femoral Stem and Cobalt-Chromium Femoral Stem in Cemented Hip Arthroplasty

A Comparison Between Titanium Femoral Stem and Cobalt-Chromium Femoral Stem in Cemented Hip Arthroplasty. A Randomized Prospective Roentgen Stereogrammetric Analysis.

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00120952
Enrollment
0
Registered
2005-07-19
Start date
Unknown
Completion date
2010-01-31
Last updated
2022-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

RSA, Osteoarthritis, Hip arthroplasty, DEXA, Titanium, Cobalt chromium, Bone cement

Brief summary

In this randomised study, the migration of a specific cemented titanium femoral stem will be compared with a similar cemented cobalt-chromium stem using Roentgen stereogrammetric analysis (RSA). In addition, the periprosthetic bone mineral density (BMD) will be evaluated to point out any interference from the modulus of the stem investigated.

Interventions

DEVICEBi-Metric femoral implant (titanium versus cobalt-chromium)

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Primary osteoarthritis of the hip * Spinal anesthesia * Informed written consent

Exclusion criteria

* Neuromuscular disease in the affected leg * Vascular disease in the affected leg * Fracture sequelae in the affected hip * Weight over 100 kg * Regular non-steroid anti-inflammatory drug (NSAID) intake in the postoperative period

Design outcomes

Primary

MeasureTime frame
Migration of femoral components evaluated by RSA

Secondary

MeasureTime frame
Periprosthetic BMD changes evaluated by DEXA

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026